{
  "pmid": "41419094",
  "title": "Cardio-renal Outcomes in Type 2 Diabetes Patients with Advanced Chronic Kidney Disease on SGLT2 inhibitors or GLP-1 receptor agonists.",
  "abstract": "GLP-1 RA and SGLT2i have demonstrated cardio-renal protective effects in randomized clinical trials. However, their comparative cardio-renal benefits in diabetes patients with stage 4-5 chronic kidney disease remain underexplored. This is a retrospective study with target trial emulation design using TriNetX platform. Adults type 2 diabetes mellitus, stage 4-5 chronic kidney disease patients who were new initiation of GLP-1 RA compared to SGLT2i were enrolled. major adverse kidney events (MAKE), major adverse cardiovascular events (MACE), and all-cause mortality. Hazard ratios (HRs) were calculated for outcomes in 1:1 propensity score-matched patients. A total of 7,458 participants were included in each group, with a mean eGFR of 23-24 mL/min/1.73 mÂ². New users of GLP-1 RAs had a higher HR for MAKE (HR 1.05, 95% CI 1.0-1.1) & dialysis (HR 1.09, 95% CI 1.03-1.15), but similar HRs for all-cause mortality (HR 0.98, 95% CI 0.91-1.05) and MACE (HR 0.97, 95% CI 0.93-1.01) compared with SGLT2i users, despite a lower HR for heart failure (HR 0.94, 95% CI 0.90-0.99). Among new GLP-1 RA users, higher HRs for MAKE occurred in subgroup of males and patients without heart failure. In patients with type 2 diabetes and stage 4-5 chronic kidney disease, initiating an SGLT2i, relative to a GLP-1 RA, was associated with a lower risk of adverse kidney events and comparable cardiovascular and mortality risks. Further studies are warranted to confirm these findings.",
  "disease": "chronic kidney disease"
}